Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, ...

The tumor microenvironment modulation market is poised for growth driven by increasing focus on advanced immunotherapies, tumor biology understanding, and combination cancer treatments. Expansion is ...

Ad Hoc Announcement Pursuant to Art.?53 LR Geneva, Switzerland, July 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing ...

Optical interconnects, leveraging intrinsic advantages such as high bandwidth, low loss, and immunity to electromagnetic interference (EMI), are thus regarded as a promising solution to these barriers ...

Wi-Fi standards remain as confusing as ever.

UK companies shipping to the EU have just over a month to be ready for new packaging waste rules – which could significantly ...

Alan Carleton, full professor in the Department of Basic Neurosciences and member of the Synapsy Centre for Mental Health ...

Researchers discovered that a potential drug developed at Michigan Medicine treats severe fatty liver disease by improving gut health, according to a study published in The Journal of Clinical ...

Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...

The gut microbiome is no longer viewed as a mere spectator in cancer development – it is increasingly recognized as a key ...

New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with ...

The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials ...